Pharma Focus Asia

Kaken Pharmaceutical and Tai Tien Pharmaceuticals Enter into a distribution Agreement for Clenafin/Jublia in Taiwan

Wednesday, November 08, 2017

Kaken Pharmaceutical Co., Ltd. and Tai Tien Pharmaceuticals Co., Ltd., which is a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation (head office Chuo-ku, Osaka; President and Representative Director Masayuki Mitsuka), announced today that Kaken and Tai Tien concluded an exclusive distribution agreement for the topical formulation for Onychomycosis “Clenafin / Jublia” (“Product” ) in Taiwan.

The Product contains efinaconazole, which is new triazole anti-fungal compound discovered by Kaken, as the active ingredient. Efinaconazole has low binding affinity with keratin, the main component of nails, meaning that the Product has superior nail-penetrating properties.

The Product was launched under the trade name of Clenafin in Japan by Kaken in 2014. Overseas, the Product was launched under the trade name of Jublia, in the United States and Canada by Valeant Pharmaceutical International, Inc. in 2014 and in Korea by Dong-A ST Co., Ltd. in 2017.

According to the agreement, Kaken hereby grants to Tai Tien the exclusive right for sales of the Product in Taiwan. Tai Tien expects to launch the Product in 2018.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Asia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024